Chairs: C.H. Bangma, NL - L.J. Denis, BE
Co-Chairs: L. Klotz, CAN - C. Parker, UK
ESO Prostate Cancer Programme Coordinatoor: R. Valdagni, IT
Scientific Coordinators: M.J. Roobol, NL - E.W.Steyerberg, NL
Welcome to Rotterdam in The Netherlands!
Over the last 5 years there has been increasing acceptance of Active Surveillance for prostate cancer as alternative to invasive treatment for men with low risk prostate cancer. Unless the overdiagnosis of indolent disease is reduced by alternative diagnostic strategies for early prostate cancer, active surveillance will continue to play an important role. In selecting men for active surveillance programs, a balance is sought between minimizing the risk of tumor progression and maximizing the number of men that will remain asymptomatic and untreated for the rest of their lives. The challenge is to determine how new imaging methods, and biomarkers, can improve patient selection, and how drug intervention may improve outcome.
This ESO Inside Track Conference on Active Surveillance will be an interactive educational activity in which attendees will enjoy presentations by internationally renowned principle investigators of active surveillance programs. You will meet the specialists who have developed or evaluated technologies that may alter the selection and monitoring of patients. And you will participate in workshops that vary from protocols to psychology.
The approach of active surveillance has become a ferment of development, with research activities in many areas. Basic and translational scientists throughout the Western world are evaluating new biomarkers to better predict the natural history of individual prostate cancers. Genetic, proteomic, and systems biology approaches are being tested. Phenomenal developments in imaging, particularly multi-parametric MRI and enhanced ultrasound, show great promise in identifying patients with more aggressive disease. Recent large scale studies on the natural history of prostate cancer have many implications for patient management. The potential role of 5 ARIs and other ‘preventive’ strategies are of great interest. The psychological impact of non-treatment on patients diagnosed with prostate cancer, and the effect of this on quality of life, has received more attention recently. Finally, a number of economic models of surveillance have been developed.
The goal of these sessions is the same: to understand how to better manage and advise men with low risk prostate cancer that likely will remain indolent.
On behalf of the European School of Oncology (ESO) we would like to thank the European Association of Urology (EAU), and Europa Uomo, the European Prostate Coalition for their participation. Together we are working to improve the outcome of patients with prostate cancer.
On behalf of the Scientific Coordinators, the Co-Chairs, and the organizing team, we wish you a productive and enjoyable Conference.
Chris Bangma and Laurence Klotz
• Overdetection and overtreatment
• Active surveillance programs worldwide
• Selection and monitoring for active surveillance
• Application of emerging technologies and biomarkers for screening and surveillance
• Psychosocial considerations on active surveillance programs
• The urologist dealing with active surveillance
• International registry studies with tissue collection
• To define the state of the art of active surveillance in prostate cancer
• To evaluate the application of active surveillance in daily clinical practice
• To determine the future research trends within the oncology community
Urologists, radiation oncologists, medical oncologists, biostatisticians, pathologists, investigators in outcomes research and genomics.
Prostate Cancer Programme
European School of Oncology (ESO)
Via del Bollo, 4
20123 Milan (Italy)
Telephone: +39 02 85464527
Facsimile: +39 02 85464545
Programme, organisation and abstracts:
Rita De Martini - firstname.lastname@example.org - Tel:+39 02 85464527 - Fax: +39 02 85464545
Laura Richetti - ESO Bellinzona Office - email@example.com -Fax +41 91 811 8051
Engels (7th floor)
Stationsplein 45 - 3013 AK Rotterdam, NL
Engels is located in Rotterdam Railway Station Square
All participants will be issued a certificate of attendance at the close of the Conference.
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
The official language of the Conference will be English. No simultaneous translation will be provided.
Your name badge is the only official evidence of registration and should be worn at all times during the Conference.
The organisers bear no responsibility for untoward events in relation with the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.
ESO is particularly grateful to the following sponsors for having provided grants to support the Conference:
Chris H. Bangma, Professor and Chair of Urology, Erasmus Medical Center, Rotterdam, NL
Lara Bellardita, Prostate Cancer Programme, Istituto Nazionale dei Tumori, Milan, IT
Peter R. Carroll, Professor and Chair of UCSF, Department of Urology, Ken and Donna Derr-Chevron Distinguished Professor, UCSF School of Medicine, San Francisco, US
Louis Denis, Secretary Europa Uomo, Oncology Centre Antwerp, BE
Mark Emberton, Professor in Urology, UCLH/UCL Comprehensive Biomedical Research Centre, London, UK
Caroline Hoeks, Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, NL
Guido Jenster, Associate Professor in Urology, Erasmus Medical Center, Rotterdam, NL
Yoshiyuki Kakehi, Professor and Chairman of Urology, Kagawa University School of Medicine, Kagawa, JP
Michael W. Kattan, Chair of Quantitative Health Sciences, Cleveland Clinic, Cleveland, US
Laurence H. Klotz, Professor of Surgery, Division of Urology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, CA
Ida Korfage, Assistant Professor of Epidemiology, Department of Public Health, Erasmus Medical Center, University Medical Centre, Rotterdam, NL
Theo van der Kwast, Professor in Pathology, Princess Margaret Hospital, University Health Network, Toronto, CA
Athene Lane, Senior Research Fellow, School of Social and Community Medicine, University of Bristol, Bristol, UK
Chris Parker, Clinical Oncologist, Academic Urology Unit, The Royal Marsden NSH Foundation Trust, Sutton, London, UK
Tom Pickles, Professor and Radiation Oncologist, Division Radiation Oncology, BC Cancer Agency, Vancouver, CA
Antti Rannikko, Associate Professor in Urology, Helsinki University, Helsinki, FI
Monique Roobol, Associate Professor Urology/Epidemiology, Erasmus Medical Center, Rotterdam, NL
Fritz H. Schröder, Professor of Urology, Erasmus Medical Center, University Medical Center, Rotterdam, NL
Axel Semjonow, Professor in Urology, Prostate Center, University Clinic Munster, DE
Ewout Steyerberg, Professor of Medical Decision Making, Department of Public Health, Erasmus Medical Center, University Medical Center, Rotterdam, NL
B.J. Trock, Director Division of Epidemiology, Johns Hopkins School of Medicine, Baltimore,US
Riccardo Valdagni, Chair Prostate Cancer Programme and Division of Radiation Oncology, Istituto Nazionale Tumori, Milan, IT
Welcome and Objectives
|Prostate Cancer Programme - European School of Oncology|
R. Valdagni, IT
|OVER-DETECTION AND OVER-TREATMENT |
Chair: F. Schröder, NL
Setting the stage: over-detection in cancer
How to reduce the number needed to treat in prostate cancer screening
OVERVIEW OF THE EUROPEAN, NORTH AMERICAN, AND JAPANESE ACTIVE SURVEILLANCE STUDIES
Y. Kakehi, JP
|10:20||North America |
T. Pickles, CA
|SELECTION AND MONITORING FOR ACTIVE SURVEILLANCE|
Chair: P. Carroll, US
Definition of criteria for indolent disease
Predictive models for selecting candidates for Active Surveillance
|PSA kinetics and surveillance: is it a useful trigger?|
L. Klotz, CA
|Biopsy alterations to identify higher risk prostate cancer patients in Europe|
C. Parker, UK
|Prediction models for outcome|
M.W. Kattan, US
|What errors do we make in assigning men for Active Surveillance?|
P. Carroll, US
|Panel Discussion |
Questions and Answers
|Lunch onsite and Poster Session|
|Best two poster presentations|
|APPLICATION OF EMERGING TECHNOLOGY AND BIOMARKERS FOR SCREENING AND SURVEILLANCE|
Chair: T. Pickles, CA
Circulating Biomarkers - Application for cancer risk and progression
|Translating genome science to the clinic|
G. Jenster, NL
|MRI (and ultrasonography): which lesions to biopsy, and how?|
C. Hoeks, NL
|Can MRI replace serial biopsies, and how to prove that?|
M. Emberton, UK
|PANEL DISCUSSION: INTERNATIONAL REGISTRY STUDY POTENTIAL|
Chair: M. Roobol, NL - T. van der Kwast, CA
Panelists: J. Kakehi, JP - L. Klotz, CA - C. Parker, UK - A. Semjonow, DE - A. Rannikko, FI
R. Valdagni, IT
EAU LECTURE "THE UROLOGIST DEALING WITH ACTIVE SURVEILLANCE"
Lecturer: A. Semjonow, DE
|PSYCHO-SOCIAL CONSIDERATIONS OF ACTIVE SURVEILLANCE PROGRAMS |
Chair: L. Denis, BE
Quality of Life outcome in Active Surveillance
|The coping skills of men with early stage prostate cancer in Active Surveillance|
L. Bellardita, IT
|Men’s experience of long term Active Surveillance within the protect trial|
A. Lane, UK
|Active Surveillance - European Support|
L. Denis, BE
Questions and answers
11:00 - 13:00 Simultaneus Workshops
Workshop #1 “Patient selection for Active Surveillance based on indolent disease definitions”
|Workshop #2 “International registry study with tissue collection”|
M. Roobol, NL - T. van der Kwast, NL
|Workshop #3 “Randomized clinical trials – How to incorporate agents into Active Surveillance programs |
F. Schroder, NL - J. Kakehi, JP
|Workshop #4 “Patients considerations in Active Surveillance Program”|
I. Korfage, NL - L. Denis, BE
|Workshop #5 “Application of emerging technology and biomarkers for Screening and Surveillance|
M. Emberton, UK - C. Hoeks, NL
REPORTS FROM INDIVIDUAL WORKING GROUPS AND DISCUSSION
|DISCUSSION BY ALL - CONSENSUS BUILDING|
|CLOSED CONSENSUS MEETING OF THE FACULTY|
The abstract submission is now closed (18 September 2011)
Participants are invited to submit an abstract on research relating to identifying potentially indolent prostate cancer or on clinical studies in investigating active surveillance for prostate cancer patients.
Abstracts will be considered for poster presentation only.
Ample opportunity will be given to review all posters by Conference participants, Chair of the Poster Session will visit all posters where there will be the possibility to give a short oral explanation of the research described (no slides).
Two best Poster presentations will be selected and presented at the audience as oral presentation (six minutes each) on Thursday, 12 January at 14.45 and a prize of € 200 each will be assigned.
Abstracts selected for poster presentations will be published in the Conference Programme Book.
• The abstracts should be limited to 2000 characters, including the title.
• The title should be in lower case letters
• Each author should be listed with First name, followed by Family Name
• The first author should be underlined (first author = corresponding author and presenter)
• List affiliation after the author’s list
• The full address with e-mail address, phone and fax number of the first author (+corresponding author and presenter) must be provided. The first author will receive an acknowledgment of receipt and all subsequent
communication by e-mail
• For abstracts accepted for poster presentation, the first author will be the presenting author and is requested to register and participate in the Conference
• It is responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made
• The acknowledgement of receipt of abstract will follow the submission. The outcome will be notified by 15 October to the first author who will be required to register to the Conference (early registration deadline, 30 October)